NASDAQ:TLRYTilray Stock Price, Forecast & News

Tilray's stock was trading at $7.09 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, TLRY shares have increased by 4.8% and is now trading at $7.43.
View which stocks have been most impacted by Coronavirus.

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tilray in the last year. There are currently 2 sell ratings, 11 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Tilray.

Tilray is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020.
View our earnings forecast for Tilray.

Tilray will be holding an earnings conference call on Monday, August 10th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Tilray Inc (NASDAQ:TLRY) posted its quarterly earnings results on Monday, May, 11th. The company reported ($1.73) earnings per share for the quarter, missing the consensus estimate of ($0.44) by $1.29. The business earned $52.20 million during the quarter, compared to analyst estimates of $49.37 million. Tilray had a negative net margin of 241.79% and a negative return on equity of 62.82%. The firm's revenue was up 127.0% on a year-over-year basis. During the same period last year, the business posted ($0.27) earnings per share.
View Tilray's earnings history.

15 analysts have issued 12 month target prices for Tilray's stock. Their forecasts range from $4.00 to $31.00. On average, they expect Tilray's stock price to reach $12.77 in the next twelve months. This suggests a possible upside of 71.9% from the stock's current price.
View analysts' price targets for Tilray.

News stories about TLRY stock have been trending somewhat positive this week, InfoTrie Sentiment reports. The research firm identifies positive and negative news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Tilray earned a news impact score of 1.8 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term.
View the latest news about Tilray.

Some companies that are related to Tilray include Cronos Group (CRON), USANA Health Sciences (USNA), Aphria (APHA), Aurora Cannabis (ACB), Canopy Rivers (RIV), Chromadex (CDXC), Mediwound (MDWD), Sundial Growers (SNDL), Happiness Biotech Group (HAPP), Natural Alternatives International (NAII), Mannatech (MTEX), Cyanotech (CYAN), FitLife Brands (FTLF), True Drinks (TRUU) and Tauriga Sciences (TAUG).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Tilray investors own include Canopy Growth (CGC), Cronos Group (CRON), Aurora Cannabis (ACB), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Netflix (NFLX), Advanced Micro Devices (AMD), Aphria (APHA) and Square (SQ).

(TLRY) raised $135 million in an IPO on Thursday, July 19th 2018. The company issued 9,000,000 shares at $14.00-$16.00 per share. Cowen and Company served as the underwriter for the IPO and Roth Capital Partners and Northland Securities were co-managers.

Tilray trades on the NASDAQ under the ticker symbol "TLRY."

Tilray's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Stelac Advisory Services LLC (0.05%), Leap Investments LP (0.02%), Wedbush Securities Inc. (0.02%), Exane Derivatives (0.01%), AdvisorShares Investments LLC (0.01%) and Aua Capital Management LLC (0.01%). Company insiders that own Tilray stock include Brendan Kennedy, Christine StClare, Edward Wood Pastorius Jr, Mark Castaneda and Michael Auerbach.
View institutional ownership trends for Tilray.

TLRY stock was sold by a variety of institutional investors in the last quarter, including AdvisorShares Investments LLC. Company insiders that have sold Tilray company stock in the last year include Brendan Kennedy, and Michael Auerbach.
View insider buying and selling activity for Tilray.

TLRY stock was acquired by a variety of institutional investors in the last quarter, including Leap Investments LP, Wedbush Securities Inc., Aua Capital Management LLC, National Asset Management Inc., Stelac Advisory Services LLC, and Exane Derivatives.
View insider buying and selling activity for Tilray.

Shares of TLRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of TLRY stock can currently be purchased for approximately $7.43.

Tilray has a market capitalization of $927.72 million and generates $166.98 million in revenue each year. The company earns $-321,170,000.00 in net income (profit) each year or ($1.69) on an earnings per share basis. Tilray employs 1,646 workers across the globe.

The official website for Tilray is www.tilray.com.

Tilray's mailing address is 1100 MAUGHAN ROAD, NANAIMO A1, V9X 1J2. The company can be reached via phone at 206-432-9325.